Stroke Trial, Recruiting NCT07166731 Sponsor: Acandis GmbH Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT07166731
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with an acute stroke caused by reduced blood flow to the brain, or a sudden loss of blood supply to the eye, within the last two weeks
  • People whose stroke or eye event appears to be linked to a specific type of fatty deposit (plaque) in the carotid artery on the same side as the affected area, where the plaque is causing a 10–49% narrowing of the artery
  • People where no other clear cause for the stroke has been found (such as a heart or large blood vessel source), based on standard heart and blood vessel tests
  • People whose carotid artery plaque shows high-risk features on a CT scan or MRI — specifically, at least two of the following: plaque thickness of 3mm or more, irregular plaque surface, ulceration, less than 50% calcification, or a fatty core; OR at least one of the following: bleeding within the plaque
  • People whose carotid artery shows a specific shelf-like or smooth ridge-like abnormality known as a carotid web
  • People whose plaque imaging results have been reviewed and confirmed by an independent review centre
  • People aged 18 or older
  • People whose level of physical disability at the time of joining the trial is mild to moderate (confirm with trial site)
  • People who are already receiving dual antiplatelet therapy (two types of blood-thinning medication) as part of their standard care before any procedure

Who may not be able to join:

  • People who have a complete blockage of the carotid artery requiring emergency treatment
  • People whose stroke involved blood vessel territories other than the carotid artery on the affected side
  • People whose stroke is likely to have been caused by small vessel disease, major artery narrowing of 50% or more, a clot from the heart, or another known condition such as blood vessel inflammation
  • People whose plaque is made up of 50% or more calcium deposits, as seen on CT scan
  • People who have a blood clot sitting inside the carotid artery
  • People whose blood vessels are very curved or twisted (more than 90 degrees), which may make safe placement of a stent difficult
  • People who have previously had a carotid surgery or stent procedure and have developed narrowing again at the same site
  • People with blood clotting disorders
  • People for whom reaching the affected area of the carotid artery is not possible, or carries a higher than acceptable risk
  • People whose plaque is located at the very beginning (opening) of the main carotid artery
  • People with a known allergy to nickel-titanium (the material used in the stent)
  • People with a known allergy to heparin (a blood-thinning medication)
  • People with any condition that reduces life expectancy to less than 12 months
  • People with any condition that increases the risk of endovascular (stent-based) procedures
  • People who would not be able to attend follow-up clinic visits each year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 (0) 7231 - 155 00 171

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Acandis GmbH
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
31 May 2032

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Primary Endpoint as rate of events of ipsilateral recurrent ischemic stroke or ipsilateral retinal artery ischemia analysed as time to first occurence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov